🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

🔬 Big news from #EHA2025! The RedirecTT-1 trial tested talquetamab + teclistamab in relapsed/refractory #myeloma with extramedullary disease. 📽️MPE spoke with Dr. Shaji Kumar (Mayo Clinic) to break down what this means for patients. 👉Watch: youtu.be/iU9U9ztp72E

What do #CARTITUDE-1 results mean for myeloma patients? What’s next in CARTITUDE-4, -5 and -6? 🔬 Dr. Sundar Jagannath (Mount Sinai, NY) explains it simply—for patients, caregivers and advocates. ▶️ youtu.be/RCvk_CGyKEo

🎙️ MPE spoke with Francesco Sparano, from Fondazione GIMEMA Franco Mandelli onlus, about the GIMEMA-CLARITY study, linking #QualityOfLife to socio-economic status in #myeloma patients, presented at #EHA2025 in Milan. Watch the interview 👇🏼 🔗 youtu.be/Ig3FQifCbm0?si…

📅 Register now for our #EHA2025 highlights webinar! 🗓️ 24 June | 🕔17:00 CET Dr. Ulf-Henrik Mellqvist, Haematologist at Sahlgrenska University Hospital, Sweden, will summarise the key #myeloma news from the congress. 👉 Register: mpeurope.org/join-our-eha-2…

Last chance to register for our #EHA2025 highlights webinar! 🗓️ 24 June | 🕔17:00 CET Dr. Ulf-Henrik Mellqvist, Haematologist at Sahlgrenska University Hospital, Sweden, will summarise the key #myeloma news from the congress. 👉 Register: mpeurope.org/join-our-eha-2…

📢 EU Medicines Agency’s CHMP issues positive opinion on daratumumab (Darzalex®) for high-risk smouldering #myeloma. This could enable earlier treatment to reduce the risk of disease progression. 🔗 mpeurope.org/ema-chmp-gives…

New guidelines for Drs. and HCP’s in the treatment and the management of #myeloma ✅14 new treatment regimens ✅Enhanced first-line therapy recommendations ✅More options for relapsed patients, including CAR-T ✅ Harmonised care across Europe Read more mpeurope.org/new-guidelines…

The FDA’s ODAC voted against the current benefit-risk profile of #Blenrep. Approval of this novel therapy is still pending. The MMRF continues to champion safety, equitable access, shared decision-making & team-based care in the development of new #myeloma therapies.

A huge thank you to all our MPE members who joined us in person at our CEE workgroup meeting yesterday in Zurich. It was an inspiring day of discussion, exchange and forward planning. A report and actions from the meeting will be available soon! #myeloma #patientadvocacy